RTS malaria vaccine

Also Known As:

MosQUIRIX; Plasmodium falciparum malaria vaccine 257049; RTS,S AS; RTS,S AS01E; RTS,S AS02D; RTS,S malaria vaccine; RTSS AS; RTSS AS01E; RTSS AS02D; RTSS malaria vaccine; S vaccine, anti-malaria; SB257049

Networked: 74 relevant articles (14 outcomes, 22 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Complex Mixtures: 1906
- Biological Products
  - Vaccines: 124365
    - Protozoan Vaccines
      - Malaria Vaccines: 895
        RTS malaria vaccine: 74

Experts

1.	Lievens, Marc: 19 articles (01/2022 - 03/2007)
2.	Vekemans, Johan: 18 articles (10/2020 - 11/2007)
3.	Leach, Amanda: 16 articles (01/2018 - 03/2007)
4.	Cohen, Joe: 11 articles (01/2013 - 03/2007)
5.	Dobaño, Carlota: 10 articles (01/2022 - 01/2017)
6.	Jongert, Erik: 10 articles (01/2022 - 10/2010)
7.	Moncunill, Gemma: 10 articles (01/2022 - 01/2017)
8.	Ofori-Anyinam, Opokua: 9 articles (09/2022 - 10/2009)
9.	Asante, Kwaku Poku: 9 articles (01/2022 - 10/2010)
10.	Campo, Joseph J: 9 articles (01/2022 - 01/2017)

Related Diseases

1.	Malaria 01/01/2022 - "All RTS,S/AS01E regimens provided substantial, similar protection against clinical malaria, suggesting potential flexibility in the recommended dosing regimen and schedule. " 02/01/2011 - "RTS,S/AS01E confers sustained efficacy for at least 15 months and shows promise as a potential public health intervention against childhood malaria in malaria endemic countries. " 10/07/2022 - "In order to help optimise the timing of these two interventions, trial data were reanalysed to estimate the duration of protection against clinical malaria provided by RTS,S/AS01E when deployed seasonally, by comparing the group who received the combination of SMC and RTS,S/AS01E with the group who received SMC alone. " 03/21/2013 - "Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure." 01/01/2011 - "Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria."
2.	Infections 11/03/2007 - "68 first or only P falciparum infections were documented: 22 in the RTS,S/AS02D group and 46 in the control group. " 10/15/2021 - "A phase IIA extension study evaluating the effect of booster vaccination with a fractional dose of RTS,S/AS01E in a controlled human malaria infection challenge." 10/13/2020 - "A Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S/AS01E and RTS,S/AS01B Delayed Fractional Dose Regimens in Malaria-Naive Adults." 11/08/2011 - "In a Phase 2a trial of the RTS,S/AS vaccine, we described significant association between protection against infection and vaccine-induced CD4 T cells. " 12/11/2008 - "During the 6-month period after the third dose of vaccine, the efficacy of the RTS,S/AS02D vaccine against first infection with P. "
3.	Rabies (Hydrophobia) 02/01/2011 - "A mean of 15 months (range 12-18 months) data were available for 172 children in the RTS,S/AS01E group and 155 in the rabies group. " 02/01/2011 - "At 12 months after the third dose, anti-circumsporozoite antibody titre data were available for 390 children in the RTS,S/AS01E group and 391 in the rabies group. " 01/01/2022 - "Children were randomly assigned (1:1:1:1:1) using a web-based randomisation system with a minimisation procedure accounting for centre to receive rabies control vaccine (M012 schedule) or two full doses of RTS,S/AS01E at month 0 and month 1, followed by either full doses at months 2 and 20 (group R012-20 [standard regimen]), full doses at months 2, 14, 26, and 38 (R012-14), fractional doses at months 2, 14, 26, and 38 (Fx012-14), or fractional doses at months 7, 20, and 32 (Fx017-20). " 01/01/2017 - "Cellular responses recognizing the RTS,S/AS01E-containing circumsporozoite protein (CSP) and Hepatitis B surface antigen (HBsAg) were assessed before and 1 month after primary vaccination by intracellular cytokine staining and 16-color flow cytometry in 105 RTS,S/AS01-vaccinated and 74 rabies-vaccinated participants (controls) in a pediatric phase III trial in Africa. "
4.	Falciparum Malaria (Plasmodium falciparum Malaria) 01/01/2023 - "In October, 2021, WHO recommended that the RTS,S malaria vaccine, with its strong safety profile and high impact, be provided to children from age 5 months in regions with moderate to high Plasmodium falciparum malaria transmission. " 01/01/2018 - "The RTS,S/AS01 malaria vaccine (Mosquirix) reduces the incidence of Plasmodium falciparum malaria and is intended for routine administration to infants in Sub-Saharan Africa. " 03/01/2012 - "Mosquirix (RTS,S): a novel vaccine for the prevention of Plasmodium falciparum malaria." 10/15/2021 - "We previously demonstrated that RTS,S/AS01B and RTS,S/AS01E vaccination regimens including at least one delayed fractional dose can protect against Plasmodium falciparum malaria in a controlled human malaria infection (CHMI) model, and showed inferiority of a two-dose versus three-dose regimen. " 01/01/2023 - "The WHO recommends use of the RTS,S/AS01E (RTS,S) malaria vaccine for young children living in areas of moderate to high Plasmodium falciparum malaria transmission and suggests countries consider seasonal vaccination in areas with highly seasonal malaria. "
5.	Hepatitis B 10/31/2018 - "Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children." 01/01/2020 - "Hepatitis B priming with the RTS,S/AS01E vaccine was effective and resulted in a memory response to HBsAg as shown by the robust booster response following an additional dose of HepB vaccine. " 01/01/2018 - "All RTS,S/AS01E groups plus a control group (without RTS,S/AS01E) received Bacillus Calmette-Guérin + oral poliovirus vaccine at ≤7 days, diphtheria, tetanus, whole-cell pertussis, hepatitis B and Haemophilus influenzae type b vaccine + oral poliovirus vaccine at 6, 10, and 14 weeks and measles vaccine at 9 months; one RTS,S/AS01E group and the control additionally received hepatitis B vaccination at ≤7 days. " 01/01/2020 - "To evaluate the impact of RTS,S/AS01E when implemented in the Expanded Program of Immunization, infants 8-12 weeks old were randomized to receive either RTS,S/AS01E or a licensed hepatitis B control vaccine (HepB), both co-administered with various combinations of the following childhood vaccines: diphtheria-tetanus-acellular pertussis-Haemophilus influenzae type b, trivalent oral poliovirus, pneumococcal non-typeable Haemophilus influenzae protein D conjugate and human rotavirus vaccine. "

Related Drugs and Biologics

1.	Vaccines
2.	Malaria Vaccines
3.	Antigens
4.	Rabies Vaccines (Rabies Vaccine)
5.	Immunoglobulin G (IgG)
6.	Cytokines
7.	Proteins (Proteins, Gene)
8.	Hepatitis B Surface Antigens (HBsAg)
9.	Intercellular Signaling Peptides and Proteins (Growth Factors)
10.	Chemokines

Related Therapies and Procedures

1.	Chemoprevention
2.	Insecticide-Treated Bednets